INNOVATE (VATE) Q3 2025 earnings summary

Executive summary

• Q3 2025 consolidated revenue rose 43.3% year-over-year to $347.1M, led by strong Infrastructure performance, while net loss attributable to shareholders narrowed to $9.4M from $15.3M in Q3 2024.

• Adjusted EBITDA increased to $19.8M from $16.8M year-over-year, reflecting gains in Infrastructure and Life Sciences.

• Strategic refinancing in August 2025 extended debt maturities but triggered sales processes for DBM Global and HC2 Broadcasting due to missed milestones.

• DBMG's adjusted backlog reached $1.6B, up $0.5B since year-end 2024, with $431M added for two new projects post-Q3.

• MediBeacon secured full regulatory approval in China for its Lumitrace injection, expanding market potential.

Financial highlights

• Infrastructure revenue grew 45.4% to $338.4M, with Q3 Adjusted EBITDA of $23.5M and net income of $8.8M.

• Life Sciences Q3 revenue was $3.1M, up 3.3% year-over-year, with R2 Technologies showing strong international and unit sales growth.

• Spectrum revenue declined to $5.6M, with Adjusted EBITDA down to $1.0M; new channel launches and datacasting initiatives underway.

• Consolidated gross profit for Q3 2025 was $49.7M, up from $48.2M in Q3 2024.

• Cash and cash equivalents at quarter-end were $35.5M, down from $48.8M at year-end 2024.

Outlook and guidance

• Spectrum segment expects advertising sales recovery in Q4, with early signs of improvement.

• MediBeacon anticipates TGFR system sales in China before year-end.

• Management is exploring asset sales and capital raises to address debt maturities and liquidity needs.

• There is substantial doubt about the ability to continue as a going concern due to near-term debt maturities and cross-default risks.

• Infrastructure aims to convert backlog to revenue and pursue new project opportunities.